1. Home
  2. TXMD vs NEUP Comparison

TXMD vs NEUP Comparison

Compare TXMD & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TherapeuticsMD Inc.

TXMD

TherapeuticsMD Inc.

HOLD

Current Price

$2.49

Market Cap

25.9M

Sector

Health Care

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.01

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TXMD
NEUP
Founded
2008
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
25.9M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TXMD
NEUP
Price
$2.49
$4.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
121.4K
33.0K
Earning Date
03-26-2026
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.03
N/A
Revenue
$2,796,000.00
$15,649,448.00
Revenue This Year
$427.09
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$91.22
N/A
Revenue Growth
75.19
N/A
52 Week Low
$0.72
$3.65
52 Week High
$2.95
$21.40

Technical Indicators

Market Signals
Indicator
TXMD
NEUP
Relative Strength Index (RSI) 56.50 44.49
Support Level $2.12 $3.98
Resistance Level $2.54 $4.11
Average True Range (ATR) 0.27 0.12
MACD -0.02 0.01
Stochastic Oscillator 36.78 10.34

Price Performance

Historical Comparison
TXMD
NEUP

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: